Compare Royalty Pharma plc Class A Ordinary Shares (RPRX) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royalty Pharma plc Class A Ordinary Shares vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Royalty Pharma plc Class A Ordinary Shares trades at $56.93 (market cap $25.27B), while iShares 20 Plus Year Treasury Bond ETF trades at $77.98 (market cap $47.61B). The key difference: iShares 20 Plus Year Treasury Bond ETF is the larger of the two by market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while iShares 20 Plus Year Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Royalty Pharma plc Class A Ordinary Shares for 1 Days and iShares 20 Plus Year Treasury Bond ETF for 83 Days on average.
| RPRX | TLT | |
|---|---|---|
Market Cap | $25.27B | $47.61B |
Volume | 3,671,183 | 49,263,490 |
Sector | Health | Fixed Income |
52-Week High | $63.96 | $92.06 |
52-Week Low | $35.44 | $77.11 |
Typical Hold Time | 1 Days | 83 Days |
Enterprise Value | $32.50B | — |
Dividend Yield | 1.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TLT, the iShares 20+ Year Treasury Bond ETF, trades at $77.98, down 46% over five years amid a historic bond market selloff. The technical outlook is bearish with moving averages signaling continued pressure, while oscillators show neutral conditions. Recent news highlights Treasury yields reaching multi-decade highs above 5.3%, creating headwinds for long-duration bond funds despite recent dividend distributions.
The ETF faces significant interest rate risk as the Federal Reserve maintains higher rates, though current yields offer attractive income potential. Key risks include further rate hikes and inflation persistence, while potential catalysts include economic slowdowns that could drive bond prices higher. Institutional flows show mixed sentiment with recent large inflows despite price declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
